Akebia Therapeutics (AKBA) stock was up on Wednesday following positive results from a Phase 2 study.
Akebia Therapeutics’ Phase 2 study was testing how well vadadustat treated anemia in dialysis patients that had chronic kidney disease. The study found that the drug was able to help patients maintain safe hemoglobin levels without serious side effects.
Akebia Therapeutics had 94 patients in its Phase 2 study. Patients were separated into three groups and each group was given a different treatment. Two groups got vadadustat once a day, with one group getting a dosage of 300mg and the other 450mg. The third group was given the drug three times a week at a dosage of 450mg. They were able to maintain stable hemoglobin levels for 16 weeks.
“This study was a clear success, demonstrating the potential of vadadustat to effectively and safely treat anemia in dialysis patients switching from injectable rESA therapy,” Brad Maroni, M.D., Chief Medical Officer at Akebia Therapeutics, said in a statement. “We are impressed with the consistency in hemoglobin levels across the duration of the study, which highlights the ability of vadadustat to control and maintain hemoglobin levels in this patient population.”
AKBA shares were up 50% as of Wednesday afternoon.
More From InvestorPlace:
— Is the Under Armour Stock Split a Raw Deal for UA Owners?
— Grab These 1% Stocks while They Are Cheap
— 5 Boom or Bust Energy Stocks to Buy
